• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.了解阿尔茨海默病中的神经精神症状:诊断与治疗的挑战和进展
Front Neurosci. 2023 Sep 5;17:1263771. doi: 10.3389/fnins.2023.1263771. eCollection 2023.
2
Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.载脂蛋白 E 基因型与晚发性阿尔茨海默病的神经精神症状和综合征。
Ageing Res Rev. 2012 Jan;11(1):87-103. doi: 10.1016/j.arr.2011.06.005. Epub 2011 Jul 7.
3
Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimer's Disease: The TEAM-AD VA Cooperative Study.阿尔茨海默病患者的神经精神症状与照料者负担:TEAM-AD退伍军人事务部合作研究
J Geriatr Psychiatry Neurol. 2018 Jul;31(4):177-185. doi: 10.1177/0891988718783897. Epub 2018 Jul 2.
4
Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.轻度认知障碍和阿尔茨海默病痴呆患者的神经精神症状和脑形态。
Int Psychogeriatr. 2021 Nov;33(11):1217-1228. doi: 10.1017/S1041610221000934. Epub 2021 Aug 17.
5
The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study.阿尔茨海默病神经精神症状在五年随访期间的进展:库奥皮奥ALSOVA研究
J Alzheimers Dis. 2018;61(4):1367-1376. doi: 10.3233/JAD-170697.
6
Neuropsychiatric Symptoms of Alzheimer's Disease in Down Syndrome and Its Impact on Caregiver Distress.唐氏综合征中阿尔茨海默病的神经精神症状及其对照料者痛苦的影响。
J Alzheimers Dis. 2021;81(1):137-154. doi: 10.3233/JAD-201009.
7
Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.与需要介入治疗的阿尔茨海默病患者的神经精神症状相关的心理社会或临床人口统计学因素:CATIE-AD 研究分析。
Int J Geriatr Psychiatry. 2017 Dec;32(12):1264-1271. doi: 10.1002/gps.4607. Epub 2016 Oct 7.
8
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease.神经精神症状是阿尔茨海默病即将发生代谢衰退的早期指标。
Transl Neurodegener. 2021 Jan 4;10(1):1. doi: 10.1186/s40035-020-00225-y.
9
Common Neuropsychiatric S ymptoms in Alzheimer's Disease, Mild Cognitive Impairment, and Subjective Memory Complaints: A Unified Framework.常见神经精神症状在阿尔茨海默病、轻度认知障碍和主观记忆抱怨:统一框架。
Curr Alzheimer Res. 2023;20(7):459-470. doi: 10.2174/0115672050255489231012072014.
10
Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.治疗阿尔茨海默病认知衰退和神经精神症状的新进展。
Int J Mol Sci. 2024 May 9;25(10):5169. doi: 10.3390/ijms25105169.

引用本文的文献

1
Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction.衰老大脑中的咖啡因:认知增强、神经退行性变以及对成瘾问题的新关注
Int J Environ Res Public Health. 2025 Jul 24;22(8):1171. doi: 10.3390/ijerph22081171.
2
Association between neuropsychiatric symptoms and neurodegeneration-related plasma biomarkers in older adults with and without clinical dementia in the Democratic Republic of the Congo.刚果民主共和国患有和未患有临床痴呆症的老年人中神经精神症状与神经退行性变相关血浆生物标志物之间的关联。
Alzheimers Dement. 2025 Aug;21(8):e70530. doi: 10.1002/alz.70530.
3
The Inflammatory Nexus: Unraveling Shared Pathways and Promising Treatments in Alzheimer's Disease and Schizophrenia.炎症关联:揭示阿尔茨海默病和精神分裂症的共同途径及有前景的治疗方法
Int J Mol Sci. 2025 Jun 27;26(13):6237. doi: 10.3390/ijms26136237.
4
Exploring the Therapeutic Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) in Individuals With Alzheimer's Disease: A Comprehensive Narrative Review.探索重复经颅磁刺激(rTMS)对阿尔茨海默病患者的治疗影响:一项全面的叙述性综述。
Cureus. 2025 May 27;17(5):e84885. doi: 10.7759/cureus.84885. eCollection 2025 May.
5
Population-scale cross-disorder atlas of the human prefrontal cortex at single-cell resolution.单细胞分辨率下人类前额叶皮层的群体规模跨疾病图谱。
Sci Data. 2025 Jun 6;12(1):954. doi: 10.1038/s41597-025-04687-5.
6
Monoamine signaling and neuroinflammation: mechanistic connections and implications for neuropsychiatric disorders.单胺信号传导与神经炎症:机制联系及其对神经精神疾病的影响
Front Immunol. 2025 Apr 28;16:1543730. doi: 10.3389/fimmu.2025.1543730. eCollection 2025.
7
Criminal Behavior in Early Onset Neurodegenerative Diseases.早发性神经退行性疾病中的犯罪行为
Eur J Neurol. 2025 Apr;32(4):e70134. doi: 10.1111/ene.70134.
8
Unraveling temporal patterns of diagnostic markers and comorbidities in Alzheimer's disease: Insights from large-scale data.揭示阿尔茨海默病诊断标志物和合并症的时间模式:来自大规模数据的见解
Alzheimers Dement. 2025 Mar;21(3):e14564. doi: 10.1002/alz.14564.
9
Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease.阿尔茨海默病神经精神症状的最新进展与未来展望
Alzheimers Dement. 2025 Mar;21(3):e70079. doi: 10.1002/alz.70079.
10
The Influence of a Specialized Dementia Ward on the Treatment of Alzheimer's Disease Patients.专科痴呆病房对阿尔茨海默病患者治疗的影响。
J Pers Med. 2025 Feb 25;15(3):82. doi: 10.3390/jpm15030082.

本文引用的文献

1
Increased cognitive effort costs in healthy aging and preclinical Alzheimer's disease.健康老龄化和临床前阿尔茨海默病认知努力成本增加。
Psychol Aging. 2023 Aug;38(5):428-442. doi: 10.1037/pag0000742. Epub 2023 Apr 17.
2
A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid.丙戊酸的药理学应用及药物诱导毒性的综合综述。
Saudi Pharm J. 2023 Feb;31(2):265-278. doi: 10.1016/j.jsps.2022.12.001. Epub 2022 Dec 9.
3
Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis.抗抑郁药治疗痴呆激越的疗效与安全性比较:一项系统评价与网状Meta分析
Front Aging Neurosci. 2023 Mar 3;15:1103039. doi: 10.3389/fnagi.2023.1103039. eCollection 2023.
4
Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.美国食品药品监督管理局(FDA)批准及医疗保险限制对阿尔茨海默病抗淀粉样蛋白疗法的影响:患者预后、医疗成本及药物研发
Lancet Reg Health Am. 2023 Mar 1;20:100467. doi: 10.1016/j.lana.2023.100467. eCollection 2023 Apr.
5
Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.阿尔茨海默病:尽管存在成本和安全方面的担忧,美国食品药品监督管理局仍批准了仑卡奈单抗。
BMJ. 2023 Jan 11;380:73. doi: 10.1136/bmj.p73.
6
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
7
Pathophysiology of Alzheimer's Disease.阿尔茨海默病的病理生理学。
Psychiatr Clin North Am. 2022 Dec;45(4):663-676. doi: 10.1016/j.psc.2022.07.003. Epub 2022 Oct 14.
8
Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.阿杜卡努单抗,一种新型抗淀粉样蛋白单克隆抗体,用于治疗阿尔茨海默病:综述
Health Psychol Res. 2022 Jan 30;10(1):31925. doi: 10.52965/001c.31925. eCollection 2022.
9
Benzodiazepine use and the risk of dementia.苯二氮䓬类药物的使用与痴呆风险
Alzheimers Dement (N Y). 2022 Jul 20;8(1):e12309. doi: 10.1002/trc2.12309. eCollection 2022.
10
A Multimodal Neuroimaging and Neuropsychological Study of Visual Hallucinations in Alzheimer's Disease.阿尔茨海默病视觉幻觉的多模态神经影像学和神经心理学研究。
J Alzheimers Dis. 2022;89(1):133-149. doi: 10.3233/JAD-215107.

了解阿尔茨海默病中的神经精神症状:诊断与治疗的挑战和进展

Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.

作者信息

Pless Andrew, Ware Destany, Saggu Shalini, Rehman Hasibur, Morgan John, Wang Qin

机构信息

Department of Neuroscience and Regenerative Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States.

Department of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, United States.

出版信息

Front Neurosci. 2023 Sep 5;17:1263771. doi: 10.3389/fnins.2023.1263771. eCollection 2023.

DOI:10.3389/fnins.2023.1263771
PMID:37732300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10508352/
Abstract

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) affect up to 97% of AD patients, with an estimated 80% of current AD patients experiencing these symptoms. Common AD-associated NPS include depression, anxiety, agitation, aggression, and apathy. The severity of NPS in AD is typically linked to the disease's progression and the extent of cognitive decline. Additionally, these symptoms are responsible for a significant increase in morbidity, mortality, caregiver burden, earlier nursing home placement, and greater healthcare expenditure. Despite their high prevalence and significant impact, there is a notable lack of clinical research on NPS in AD. In this article, we explore and analyze the prevalence, symptom manifestations, challenges in diagnosis, and treatment options of NPS associated with AD. Our literature review reveals that distinguishing and accurately diagnosing the NPS associated with AD remains a challenging task in clinical settings. It is often difficult to discern whether NPS are secondary to pathophysiological changes from AD or are comorbid psychiatric conditions. Furthermore, the availability of effective pharmaceutical interventions, as well as non-pharmacotherapies for NPS in AD, remains limited. By highlighting the advance and challenges in diagnosis and treatment of AD-associated NPS, we aspire to offer new insights into the complexity of identifying and treating these symptoms within the context of AD, and contribute to a deeper understanding of the multifaceted nature of NPS in AD.

摘要

阿尔茨海默病(AD)中的神经精神症状(NPS)影响着高达97%的AD患者,据估计,目前80%的AD患者有这些症状。常见的与AD相关的NPS包括抑郁、焦虑、激越、攻击行为和淡漠。AD中NPS的严重程度通常与疾病进展及认知衰退程度相关。此外,这些症状会显著增加发病率、死亡率、照护者负担、提前入住养老院的几率以及医疗支出。尽管其患病率高且影响重大,但关于AD中NPS的临床研究明显不足。在本文中,我们探讨并分析了与AD相关的NPS的患病率、症状表现、诊断挑战及治疗选择。我们的文献综述显示,在临床环境中,区分并准确诊断与AD相关的NPS仍然是一项具有挑战性的任务。通常很难辨别NPS是继发于AD的病理生理变化还是共病的精神疾病。此外,针对AD中NPS的有效药物干预措施以及非药物疗法仍然有限。通过强调与AD相关的NPS在诊断和治疗方面的进展与挑战,我们希望能为在AD背景下识别和治疗这些症状的复杂性提供新见解,并有助于更深入地理解AD中NPS的多面性。